BioNTech SE ( BNTX) – First approved mRNA vaccine against COVID-19

The core competencies and resources developed over the last decade by the company has helped in development of first approved mRNA vaccine against COVID 19. BNT162b2 demonstrated 91.3% vaccine efficacy for cases of COVID 19.

Highlights

Valuation

– CrispIdea Forecast
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Developments

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

No of Pages : 27